ATE481091T1 - Orale zusammensetzungen zur absorption von phosphorverbindungen - Google Patents

Orale zusammensetzungen zur absorption von phosphorverbindungen

Info

Publication number
ATE481091T1
ATE481091T1 AT05810997T AT05810997T ATE481091T1 AT E481091 T1 ATE481091 T1 AT E481091T1 AT 05810997 T AT05810997 T AT 05810997T AT 05810997 T AT05810997 T AT 05810997T AT E481091 T1 ATE481091 T1 AT E481091T1
Authority
AT
Austria
Prior art keywords
phosphorus compounds
absorption
oral compositions
present
hyperphosphatemia
Prior art date
Application number
AT05810997T
Other languages
English (en)
Inventor
Vincenzo Savica
Original Assignee
Cm & D Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36035790&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE481091(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cm & D Pharma Ltd filed Critical Cm & D Pharma Ltd
Application granted granted Critical
Publication of ATE481091T1 publication Critical patent/ATE481091T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05810997T 2004-12-07 2005-11-29 Orale zusammensetzungen zur absorption von phosphorverbindungen ATE481091T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000015A ITME20040015A1 (it) 2004-12-07 2004-12-07 Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
PCT/EP2005/056289 WO2006061336A2 (en) 2004-12-07 2005-11-29 Oral compositions for absorption of phosphorus compounds

Publications (1)

Publication Number Publication Date
ATE481091T1 true ATE481091T1 (de) 2010-10-15

Family

ID=36035790

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05810997T ATE481091T1 (de) 2004-12-07 2005-11-29 Orale zusammensetzungen zur absorption von phosphorverbindungen

Country Status (21)

Country Link
US (4) US7815898B2 (de)
EP (1) EP1827386B1 (de)
JP (1) JP5049135B2 (de)
KR (1) KR101283820B1 (de)
CN (1) CN101068535A (de)
AT (1) ATE481091T1 (de)
BR (1) BRPI0518517A2 (de)
CA (1) CA2587924C (de)
CY (1) CY1110985T1 (de)
DE (1) DE602005023648D1 (de)
DK (1) DK1827386T3 (de)
ES (1) ES2352957T3 (de)
HR (1) HRP20100653T1 (de)
IT (1) ITME20040015A1 (de)
MX (1) MX2007006704A (de)
PL (1) PL1827386T3 (de)
PT (1) PT1827386E (de)
RS (1) RS51507B (de)
RU (1) RU2392926C2 (de)
SI (1) SI1827386T1 (de)
WO (1) WO2006061336A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITME20040015A1 (it) * 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
EP1951266A2 (de) 2005-09-02 2008-08-06 Genzyme Corporation Verfahren zur entfernung von phosphat und dafür verwendetes polymer
ITRM20060204A1 (it) * 2006-04-10 2007-10-11 Vincenzo Savica Farmaci e alimentei per diete normoproteiche iperproteiche ipopro teiche tutte ipofosforiche e bevande ipofosforiche
US20100135950A1 (en) * 2006-07-05 2010-06-03 Genzyme Corporation Iron(II)-Containing Treatments for Hyperphosphatemia
WO2009126145A1 (en) * 2008-04-08 2009-10-15 Cypress Pharmaceutical, Inc. Phosphate-binding chitosan and uses thereof
US7943597B2 (en) 2008-04-08 2011-05-17 Cypress Pharmaceutical, Inc. Phosphate-binding chitosan and uses thereof
US8877907B2 (en) 2010-06-07 2014-11-04 The Johns Hopkins University Molecularly imprinted polymers
US9314523B2 (en) 2010-09-21 2016-04-19 Elwha Llc Ingestible salt grabber
EP2441436A1 (de) * 2010-10-13 2012-04-18 Fresenius Medical Care Deutschland GmbH Phosphatbinderformulierung zur einfachen Einnahme
WO2012098562A2 (en) 2011-01-19 2012-07-26 Panacea Biotec Limited Liquid oral compositions of lanthanum salts
EP2699099A1 (de) 2011-04-20 2014-02-26 Gumlink A/S Kaugummi mit chitosan zur verringerung des gehalts an freien phosphorverbindungen im verdauungssaft
WO2012143008A1 (en) 2011-04-20 2012-10-26 Gumlink A/S Reduction of the level of free phosphorus compounds in the digestive juice
MX337613B (es) * 2011-06-08 2016-03-10 Kai Pharmaceuticals Inc Agentes terapeuticos para regular fosforo en suero.
JP6348495B2 (ja) * 2012-09-04 2018-06-27 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム シトレートに富むカルシウム・マグネシウム補助剤およびその使用
ES2715990T3 (es) 2013-04-12 2019-06-07 Expharma Ltd Composiciones que comprenden una mezcla de elastómeros y quitosano y uso de las mismas para el tratamiento de trastornos del metabolismo mineral de fósforo
SI3287133T1 (sl) 2013-06-05 2019-09-30 Tricida Inc. Polimeri, ki vežejo protone,za peroralno dajanje
EP2818176A1 (de) * 2013-06-27 2014-12-31 Virbac Zusammensetzung zur Behandlung progressiver Nierenkrankheiten
CN103536977A (zh) * 2013-11-04 2014-01-29 于杰 血液灌流器
US9744128B2 (en) 2014-06-05 2017-08-29 Mastix LLC Method for manufacturing medicated chewing gum without cooling
EP3593808B1 (de) * 2014-12-10 2020-12-09 Tricida Inc. Protonenbindende polymere zur oralen verabreichung
BR112018072714A2 (pt) 2016-05-06 2019-02-19 Tricida, Inc. composições de ligação a hcl para e método de tratamento de distúrbios de ácido-base
US10765658B2 (en) 2016-06-22 2020-09-08 Mastix LLC Oral compositions delivering therapeutically effective amounts of cannabinoids
SG11202003451UA (en) 2017-11-03 2020-05-28 Tricida Inc Compositions for and method of treating acid-base disorders
WO2019105401A1 (en) * 2017-11-29 2019-06-06 Shin Era Technology Co. Ltd. Enteric coated pharmaceutical composition and use thereof
US11273123B2 (en) 2018-07-18 2022-03-15 USpharma Ltd Chewable pharmaceutical dosage forms
US12390416B2 (en) 2018-07-18 2025-08-19 USpharma Ltd Chewable pharmaceutical dosage forms
CN109528764B (zh) * 2018-09-30 2021-04-06 北京市中关村医院 一种凝胶基层状无机物磷结合剂及其制备方法和用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3818807A (en) * 1972-12-06 1974-06-25 Eng Concrete Placer Inc Slurry pump piston seal
US4181718A (en) * 1975-12-29 1980-01-01 Mason Norbert S Polyanion-stabilized aluminum hydrogels
US4163777A (en) * 1977-04-29 1979-08-07 Lewis/Howe Company Controlled antacid delivery form and method of treatment therewith
US4163177A (en) * 1977-10-17 1979-07-31 Ward Derrick A Oscillation generator providing oscillations of varying amplitude
US4160820A (en) * 1977-11-28 1979-07-10 General Mills, Inc. Plaque inhibiting composition and method
US4515769A (en) * 1981-12-01 1985-05-07 Borden, Inc. Encapsulated flavorant material, method for its preparation, and food and other compositions incorporating same
US4386106A (en) * 1981-12-01 1983-05-31 Borden, Inc. Process for preparing a time delayed release flavorant and an improved flavored chewing gum composition
US4512968A (en) * 1982-11-30 1985-04-23 Lion Corporation Oral compositions
JPS61161216A (ja) * 1985-01-11 1986-07-21 Teijin Ltd キトサン類を用いた徐放性医薬品組成物
EP0187703B1 (de) * 1985-01-11 1992-08-05 Teijin Limited Präparate mit verzögerter Freisetzung
JPS62132830A (ja) * 1985-12-05 1987-06-16 Teijin Ltd 徐放性医薬品組成物
JPS63310833A (ja) * 1987-06-10 1988-12-19 Nippon Medical Supply Corp リン吸着カプセル
DE3936319C3 (de) 1989-11-01 1997-05-07 Bartz Volker Phosphatbinder zur oralen Verabreichung
US5030459A (en) * 1989-11-07 1991-07-09 Warner-Lambert Company High impact mint flavor for high base chewing gum
JP2884124B2 (ja) 1992-01-31 1999-04-19 鈴与株式会社 リン吸着剤
US5496545A (en) * 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
GB9506126D0 (en) * 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
TW528597B (en) * 1996-03-05 2003-04-21 Mitsubishi Electric Corp Medicament for preventive and/or therapeutic treatment of hyperphosphatemia
IE980990A1 (en) * 1998-11-27 2000-05-31 Fuisz Internat Ltd Composition and Method for Medicated Chewing Gum Delivery System
DE19917705C1 (de) * 1999-04-20 2000-12-28 Vitasyn Gmbh Mittel zur Therapie von Hyperphosphatämie
US6645535B2 (en) 1999-09-02 2003-11-11 Wm. Wrigley Jr. Company Method of making coated chewing gum products containing various antacids
FI121528B (fi) * 2000-10-30 2010-12-31 Biohit Oyj Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa
US20030072841A1 (en) * 2001-03-19 2003-04-17 The Procter & Gamble Campany Polybutene containing chewing gum and confection
ITMI20012320A1 (it) * 2001-11-06 2003-05-06 Perfetti Van Melle Spa Composizioni orali solide anti-tartaro e anti-placca batterica, utilicome coadiuvanti nell'igiene odonto-stomatologica
IL162823A0 (en) * 2002-01-03 2005-11-20 Yissum Res Dev Co Edible compositions capable of removing oral biofilm
US7244455B2 (en) * 2002-01-16 2007-07-17 Warner-Lambert Company Center-filled chewing gum containing a deliverable form of calcium
SE0302947D0 (sv) * 2003-01-24 2003-11-07 Magle Ab A composition material for transmucosal delivery
MXPA06002257A (es) * 2003-08-26 2006-05-17 Shire Holdings Ag Farmaceutica que comprende compuestos de lantano.
US7459502B2 (en) 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US20060177415A1 (en) * 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders
ITME20040015A1 (it) * 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
US8323683B2 (en) * 2005-05-18 2012-12-04 Mcneil-Ppc, Inc. Flavoring of drug-containing chewing gums
US20070207206A1 (en) * 2006-03-02 2007-09-06 Rice Bronwyn C Chewable pain formula

Also Published As

Publication number Publication date
DE602005023648D1 (de) 2010-10-28
US20110002858A1 (en) 2011-01-06
PL1827386T3 (pl) 2011-05-31
US8518379B2 (en) 2013-08-27
EP1827386B1 (de) 2010-09-15
WO2006061336A2 (en) 2006-06-15
MX2007006704A (es) 2008-01-16
US20080125394A1 (en) 2008-05-29
KR101283820B1 (ko) 2013-07-15
US20100316578A1 (en) 2010-12-16
ITME20040015A1 (it) 2005-03-07
RU2392926C2 (ru) 2010-06-27
CA2587924A1 (en) 2006-06-15
SI1827386T1 (sl) 2011-01-31
US20140356297A1 (en) 2014-12-04
CN101068535A (zh) 2007-11-07
JP2008523022A (ja) 2008-07-03
HRP20100653T1 (hr) 2011-01-31
CY1110985T1 (el) 2015-06-11
CA2587924C (en) 2013-08-20
KR20070090904A (ko) 2007-09-06
RU2007125702A (ru) 2009-01-20
WO2006061336A3 (en) 2006-09-14
BRPI0518517A2 (pt) 2008-11-25
RS51507B (sr) 2011-06-30
EP1827386A2 (de) 2007-09-05
PT1827386E (pt) 2010-12-03
US7815898B2 (en) 2010-10-19
DK1827386T3 (da) 2011-07-11
ES2352957T3 (es) 2011-02-24
JP5049135B2 (ja) 2012-10-17

Similar Documents

Publication Publication Date Title
CY1110985T1 (el) Στοματικες συνθεσεις για απορροφηση των ενωσεων φωσφορου
MA30531B1 (fr) Anticorps anti-dll4 et leurs procedes d'utilisation
NO20075111L (no) Farmasoytisk sammensetning
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
SE0301700D0 (sv) Novel compounds
EP1976558A4 (de) Verwendung einer immunogenen pcv2-zusammensetzung zur abschwächung von krankheitssymptomen bei schweinen
EA200801997A1 (ru) Новые соединения
EP2238985A4 (de) Hochkonzentrierte antikörperhaltige flüssige formulierung
EA201070544A1 (ru) Новый класс терапевтических веществ, усиливающих диффузию низкомолекулярных соединений
SE0301010D0 (sv) Novel compounds
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
EA200970156A1 (ru) Пиридизиноновые производные
EA200700192A1 (ru) Производные фталазина в качестве ингибиторов parp
EP2116264A4 (de) Zubereitung zur transnasalen anwendung
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
SE0301009D0 (sv) Novel compounds
NO20071901L (no) Substituerte bisykliske imidazo-3-ylamin sammensetninger
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
SE0301653D0 (sv) Novel compounds
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
EP1988090A4 (de) Imidazol-5-carbonsäurederivate, herstellungsverfahren und verwendung davon
DE602007005387D1 (de) Ptors
DE602008003788D1 (de) Neuartige rar-rezeptoragonisten-liganden und deren verwendung in der humanmedizin und kosmetik
NO20065898L (no) 1-heterocyklyl-1,5-dihydro-pyrido[3,2-b]indol-2-oner

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1827386

Country of ref document: EP